The importance of heart and brain imaging in children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C)

Sophie I. Mavrogeni1,4 · Genovefa Kolovou2 · Vasileios Tsirimpis2 · Dimitrios Kafetzis3,4 · Georgios Tsolas3 · Lampros Fotis3,4

Received: 13 February 2021 / Accepted: 17 March 2021 / Published online: 17 April 2021 © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021

Abstract
Multisystem Inflammatory Syndrome in Children (MIS-C) recently reported in a minority of children affected by SARS-CoV-2, mimics Kawasaki disease (KD), a medium vessel vasculitis of unknown cause. In contrast to acute COVID-19 infection, which is usually mild in children, 68% of patients with MIS-C will need intensive care unit. Myocarditis and coronary artery ectasia/aneurysm are included between the main cardiovascular complications in MIS-C. Therefore, close clinical assessment is need it both at diagnosis and during follow-up. Echocardiography is the cornerstone modality for myocardial function and coronary artery evaluation in the acute phase. Cardiovascular magnetic resonance (CMR) detects diffuse myocardial inflammation including oedema/fibrosis, myocardial perfusion and coronary arteries anatomy during the convalescence and in adolescents, where echocardiography may provide inadequate images. Brain involvement in MIS-C is less frequent compared to cardiovascular disease. However, it is not unusual and should be monitored by clinical evaluation and brain magnetic resonance (MRI), as we still do not know its effect in brain development. Brain MRI in MIS-C shows T2-hyperintense lesions associated with restricted diffusion and bilateral thalamic lesions. To conclude, MIS-C is a multisystem disease affecting many vital organs, such as heart and brain. Clinical awareness, application of innovative, high technology imaging modalities and advanced treatment protocols including supportive and anti-inflammatory medication will help physicians to prevent the dreadful complications of MIS-C.

Keywords MIS-C, multisystem inflammatory syndrome in children · Echocardiography · Cardiovascular magnetic resonance · Brain magnetic resonance

Sophie I. Mavrogeni
soma13@otenet.gr
Genovefa Kolovou
genovefa@kolovou.com
Vasileios Tsirimpis
vtsirimpis@yahoo.gr
Dimitrios Kafetzis
profkafetzis@gmail.com
Georgios Tsolas
geotsolas@gmail.com

Lampros Fotis
lafotis@med.uoa.gr

1 Onassis Cardiac Surgery Center, Athens, Greece
2 Metropolitan Hospital, Cardiometabolic Center, Piraeus, Greece
3 Department of Pediatrics, Metropolitan Hospital, Piraeus, Greece
4 Department of Pediatrics, National and Kapodistrian University of Athens, 1 Rimini Str, 12462 Chaidari Athens, Greece
Introduction

Multisystem Inflammatory Syndrome (MIS-C) has been recently reported in a minority of children affected by SARS-CoV-2 [1, 2]. MIS-C mimics Kawasaki disease (KD), a medium vessel vasculitis of unknown cause that affects mainly children < 5 years [3–5]. Several terminologies have been used to describe this disease including Kawasaki-like syndrome (KLS), atypical Kawasaki disease, incomplete Kawasaki disease, SARS-CoV-2-induced Kawasaki-like Hyper-inflammatory Syndrome (SCKKh Syndrome) and Kawa-COVID-19 [1, 2]. The Centers for Disease Control and Prevention (CDC), United States (US) has termed this disease as MIS-C, the World Health Organization has used the term Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19, while the Royal College of Paediatrics and Child Health have used the term PIMS-TS (paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2) [6].

Pediatric COVID-19 patients usually present with mild symptoms including cough, fever, sore throat and diarrhea, but low respiratory tract symptomatology is rather unusual, compared to adults. Fortunately, children account for only 1–5% of COVID-19 cases and more than 80% of them are asymptomatic or mildly symptomatic [7]. Mortality due to COVID-19 is also significantly lower in children, compared to adults (< 0.1% versus 5–15%). In contrast to acute COVID-19 infection, which is mild in children, 68% of MIS-C patients present an extremely severe condition and need intensive care support, due to cardiovascular complications [8]. MIS-C and KD differ in the following clinical and laboratory features. (1) Gastrointestinal complications, neurological symptoms, shock and coagulopathy are more common in MIS-C, but unusual in classic KD. (2) Classic KD is common in North East Asian, while MIS-C has been reported more commonly in patients of African, Hispanic or Latino origin. (3) KD is common in children < 5 years, while MIS-C involves children > 5 years of age (4) Low platelets, lymphopenia and high C-reactive protein (CRP) levels are common in MIS-C, but rather unusual in KD [9]. Although COVID-19 in children is mild, MIS-C is a serious condition, similar to other hyper-inflammatory syndromes in children, such as KD shock syndrome, toxic shock syndrome and macrophage activation syndrome [10]. The comparison between KD and MIS-C is presented in Table 1.

Fever, mucocutaneous findings (rash, conjunctivitis, hands/feet edema, red/cracked lips, and strawberry tongue), myocardial dysfunction, cardiac conduction abnormalities, shock, gastro-intestinal symptoms, respiratory signs and lymphadenopathy are included between the main symptoms of MIS-C [11]. In parallel, there is increasing incidence of neurologic involvement, presenting as severe headache, altered mental status, cranial nerve palsies, or meningismus [11]. These findings are non-specific and can also occur in other infectious or non-infectious causes, including

| Table 1 Comparison between KD and MIS-C |
|-----------------------------------------|
| MIS-C (WHO) | Complete KD (AHA) | Incomplete KD (AHA) |
| **Age** | 0–19 yrs | Unspecified | Unspecified |
| **Inflammation** | Fever, increased inflammatory markers > 3 days | Fever lasting > 5 days | Fever lasting > 5 days |
| Two of the following: | | Four or more principal clinical features: |
| (A) rash or bilateral non-purulent conjunctivitis or mucocutaneous inflammation signs (oral, hands, or feet); | | (A) erythema and cracking of lips, strawberry tongue or oral and pharyngeal mucosa; |
| (B) hypotension or shock; | | (B) bilateral bulbar conjunctival injection without exudate; |
| (C) myocardial dysfunction, pericarditis, valvulitis, or coronary abnormalities (including echocardiogram findings or elevated troponin or N-terminal pro B-type natriuretic peptide); | | (C) rash; |
| (D) evidence of coagulopathy (elevated prothrombin time, partial thromboplastin time, and elevated D-dimers); and | | (D) erythema and edema of the hands and feet in acute phase and periungual desquamation in subacute phase; and |
| (E) acute gastro-intestinal problems (diarrhea, vomiting, or abdominal pain | | (E) cervical lymphadenopathy |
| **Exclusion** | Other microbial cause of inflammation | | |
| SARS-Covid-2 status | Positive RT-PCR, antigen test, or serology; or any contact with patients with COVID-19 | | |

 Springer
oncologic or autoimmune disorders. Therefore, it is absolutely necessary to exclude other diseases that may present with similar clinical findings, when we perform the differential diagnosis of patients with potential MIS-C.

The aim of this review is to present cardiovascular and brain involvement and the role of imaging in the early detection of these abnormalities.

**Research strategy**

A MedLine, Embase and Scopus search was performed according to published guidance on narrative reviews [12] using the following terms: systemic autoimmune diseases, autoimmune rheumatic diseases, cardiovascular involvement, myocarditis, cardiac magnetic resonance, immunosuppressive treatment, systemic lupus erythematosus, systemic sclerosis, vasculitis, rheumatoid arthritis, ankylosing spondylitis. Original research papers and review articles focusing on the effect of immunosuppressive treatment on myocarditis. Publications not in English and data from ongoing research were excluded.

**Cardiovascular disease in MIS-C**

Cardiovascular complications and particularly left ventricular dysfunction is the commonest complication in patients with MIS-C. Cardiac biomarkers including N-terminal pro b-type Natriuretic Peptide (NT-pro-BNP) and troponin levels are extremely high, compared to KD and indicate severe myocardial damage that may lead to heart failure. Symptomatic myocarditis was found in 40–80% of patients with MIS-C [13, 14]. In contrast, symptomatic myocarditis is seen in <5% of KD patients [15–17]. Pouletty et al. documented the presence of severe myocarditis in approximately 50% of MIS-C patients with higher risk in older children [13].

Coronary artery abnormalities (CAAs) have been diagnosed in 9–24% of patients with MIS-C, as common as in KD in the intravenous immunoglobulin (IVIG) era [6, 18–21]. CAAs may present as dilatation or small-sized aneurysms in most patients. Pericarditis and valvular regurgitations are not unusual. Both NT-pro-BNP and cardiac troponin levels are extremely high in patients with MIS-C compared to KD [6, 18, 22]. In a recent study, NT-pro-BNP levels were elevated in 83% patients, while troponins in 68% of them [6].

Finally, the evaluation of 286 children from 55 centers in 17 European countries showed that cardiac involvement was common in children with MIS-C. The majority of them have significantly increased levels of NT-pro-BNP, ferritin, D-dimers and cardiac troponin in addition to high CRP and procalcitonin levels. According to this publication, children with MIS-C should be monitored for shock, cardiac arrhythmias, pericardial effusion, and coronary artery dilatation which were the 4 most common cardiovascular complications in this cohort. Despite high D-dimer levels, only a small number of MIS-C patients develop deep vein thrombosis or pulmonary embolism [23]. Furthermore, a statistically significant correlation between elevation in cardiac/biochemical indices and the need of intensive care support was found. However, compared to adults, the mortality in children with MIS-C was uncommon, despite the high levels of inflammatory indices and the multi-system presentation of the disease [24].

Children with MIS-C need to be treated in a hospital and some of them should be treated in a pediatric intensive care unit. The treatment should include supportive care and medication to reduce inflammation in affected organs and protect them from permanent damage [24].

**Electrocardiogram (ECG)**

There are only few reports about the role of electrocardiogram (ECG) in MIS-C. According to a recent study, ECG abnormalities were found in 56% of MIS-C patients. First-degree atrioventricular block (AVB) was seen in 20% of patients 6 days after the onset of fever with progression to second- or third-degree AVB, but none of them required pacemaker. No patient with AVB had an elevated troponin level. QTc prolongation was seen in 28% and nonspecific ST segment changes were seen in 56% of them. Ectopic atrial tachycardia was observed in 1 patient, and none developed ventricular arrhythmias [16].

**Echocardiography**

Due to the high incidence of cardiovascular disease (CVD) in MIS-C, echocardiography is of great value at disease diagnosis to assess the severity of cardiovascular involvement. The main findings expected in MIS-C include: (a) depressed LV function [25, 26] (b) Coronary artery abnormalities, including dilation or aneurysm [27, 28], (c) Mitral valve regurgitation, (d) Pericardial effusion [6, 25]. Comparisons between echocardiographic images in MIS-C and KD are presented in Fig. 1a, b.

Echocardiography is also of great value during follow-up. According to our experience from KD [28], in patients with normal function and normal CA dimensions, a follow-up echocardiogram should be performed two weeks post diagnosis to re-evaluate CA dimensions. In patients with CA ectasia/aneurysm at diagnosis, an echocardiogram should be repeated every week until CA dimensions
will be normalized. In children with systolic dysfunction and/or myocarditis and normal CAs at diagnosis, the echocardiogram should be repeated every month, including repeat imaging of the CAs in each study. Finally, in patients with CA abnormalities and systolic dysfunction/myocarditis at diagnosis, cardiovascular magnetic resonance imaging (CMR) should be considered in 2–6 months post MIS-C to perform ventricular function evaluation and tissue characterization [27, 28].

According to a recent publication, MIS-C behaves differently from classic KD, presenting greater incidence of myocardial injury and sparing of the coronary arteries. However, longtime evaluation of coronary arteries in MIS-C is still missing. Even in cases with preserved systolic function, there are subtle changes in diastolic function and strain parameters supporting myocardial injury. In short-term follow-up, persistence of diastolic dysfunction was observed, although the systolic function may be normalized [29]. According to other studies, the involvement of coronary arteries is not unusual in MIS-C. In one study by Kelly et al., mild coronary artery dilatation/ectasia was found [30].

**Cardiovascular Magnetic Resonance (CMR)**

CMR has the unique capability to perform coronary arteries, biventricular function and tissue characterization in the same radiation-free examination with excellent reproducibility [28]. The diagnosis of myocarditis, which represents the main lesion during MIS-C, is based on the Lake Louis (LL) criteria. LL have a diagnostic accuracy of 78% in identifying myocarditis. LL criteria include the evaluation of edema on T2-weighted images, of hyperemia and early capillary leakage on T1-weighted early gadolinium enhancement images (EGE), and of fibrosis using late gadolinium-enhanced images (LGE). LL criteria have a high specificity and positive predictive value, when 2 out of 3 indices are abnormal [31]. Myocarditis-induced alterations may present with several LGE patterns, are typically localized at the sub-epicardial or intramural areas of LV and are frequently located in the basal to mid-inferolateral wall. LGE-positive patients are at increased risk of adverse cardiac events, while LGE-negative patients usually have an excellent prognosis, independently of their symptomatology [32]. The CMR diagnostic accuracy can increase significantly using the
proposed updated LL criteria. These criteria include the addition of parametric mapping techniques (T2 mapping, T1 mapping and extracellular volume fraction = ECV). In more details, T2 mapping images can identify acute myocardial edema with higher signal-to-noise ratio, shorter breathhold time and fewer motion artifacts, compared to classic T2-W images. Native T1 mapping is sensitive to intracellular and extracellular changes in free water content and is increased during acute inflammation. Finally, ECV detects an expanded extracellular space and can assess diffuse fibrosis, missed by LGE [33]. A recent research by Puntmann et al. including 100 patients recovered from COVID-19 infection, showed that native T1 and T2 mapping provides the best parameters to detect COVID-19-related myocardial injuries [34]. In contrast to adults, myocarditis in MIS-C is characterized by diffuse edema (Fig. 2) without LGE (Fig. 3) and this should be taken under consideration, when we evaluate CMR results in MIS-C patients [35].

Coronary artery evaluation using CMR coronary angiography has been extensively used in the evaluation of coronary artery ectasia/aneurysm in KD alone or in combination with assessment of inflammation/fibrosis [36, 37]. Although echocardiographic assessment is easy and reliable, it is inadequate in adolescents, and CMR or CT coronary angiography (Fig. 4) should be considered as a noninvasive modality without radiation [28].

## Diagnosis and treatment

Previously published guidelines and management recommendations by the American College of Rheumatology (ACR) emphasize the role of biomarkers, ECG, and echocardiography both during the acute phase and the follow-up time until complete recovery of cardiac function will be noticed. Furthermore, CMR and CT should be considered in individualized cases [38]. Regarding treatment, IVIG, corticosteroids, anakinra, antiplatelets and cardiac supportive medication has been proposed [38]. All these measurements target to the rapid deterioration of the inflammatory syndrome and protection of acute and late cardiac complication that usually accompany MIS-C [38].

### Brain involvement during MIS-C

Mental alteration has been described during COVID-19 [39]. However, there are only rare reports of severe encephalopathy in MIS-C patients. A multicenter study in adults with COVID-19 and neurologic symptoms showed ischemic infarcts in 31%, intracranial hemorrhage in 6%, and nonspecific T2/fluid-attenuated inversion recovery hyperintensity [14] with restricted diffusion in a small percentage of them [39]. The revision of 187 children from six recent reports of MIS-C showed that these children had an unexpectedly high incidence (34%) of neurological involvement [13, 14, 18, 40–42]. The pathophysiologic mechanism of neurologic complications in children with MIS-C remains unclear. Potentially, the mechanism in MIS-C is different from that of the thromboembolic cerebrovascular events observed in adults with COVID-19 [43]. The pathophysiologic mechanism of MIS-C meningoencephalitis is still unknown, but it may be related to neuronal cell edema as a result of cytokine storm syndrome, due to overreaction of monocytes, macrophages, T cells and release of interleukins-6 (IL-6) post SARS-CoV-2 infection. Furthermore, it may be
related to acute necrotizing encephalopathy, a para-infection described mainly in the pediatric population [44]. Although direct invasion of central nervous system (CNS), due to COVID-19 or metabolic encephalopathy as a result of severe hypoxia has also been reported in adults [44]. However, the lack of positive SARS-CoV-2 reverse transcription polymerase chain reaction test in cerebrospinal fluid (CSF) and the mild lung involvement in these cases does not support the hypothesis of COVID-19 encephalopathy. Finally, another entity called reversible splenial lesion syndrome (RESLES) should be discussed. This is characterized by a temporary lesion in the splenium of the corpus callosum, related to encephalitis, seizures, withdrawal of antiepileptic drug, or metabolic disturbances. RESLES with mild encephalitis/encephalopathy and reversible splenial lesion has been defined as a distinct syndrome, associated with various viral infections [45].

**Brain MRI in MIS-C**

A recent study in the UK showed changes in the splenium of the corpus callosum (SCC) in all 4 patients with neurologic signs. T2-hyperintense lesions associated with restricted diffusion were seen in 3 children. The fourth patient presented with a splenial lesion on computed tomography, but on brain MRI, no restricted diffusion was found, although the signal change remained unchanged. The genu was involved in 2 patients and the bilateral centrum semi-ovale in 2 patients. Finally, spinal cord pathologic enhancement was not identified. Patient 2 had a repeated MRI on day 5 that showed resolution of diffusion restriction in the SCC and centrum semi-ovale [46]. Furthermore, a case report presented a previously healthy child with MIS-C, who developed reversible encephalopathy with moderate EEG slowing and bilateral thalamic lesions in brain MRI. The child was improved with continued anti-inflammatory treatment [47]. In another study of 47 children with MIS-C, 4/47 underwent brain MRI. One of these children, with fluctuating mental status and laboratory evidence of thrombotic microangiopathy with hemolytic anemia, had fluid-attenuated inversion recovery (FLAIR) MRI hyperintensity with restricted diffusion involving the bilateral parieto-occipital cortices with mild cortical thickening and T2/FLAIR hyperintensity in the left fronto-parietal centrum semi-ovale. A second brain MRI for evaluation of vision defects and cranial nerve palsy demonstrated MR findings compatible with papilledema. Two additional brain MRIs for evaluation of mental alterations and headache were normal [48].

**Impact of CMR and brain MRI in the MIS-C patients’ follow-up**

The severity of cardiac involvement has important implications in the patient’s future. Myocardial function deterioration may lead to future intractable heart failure, if it is incompletely treated. Furthermore, the persistence of myocardial inflammation may suggest treatment of the immunomodulatory medication. Finally, the presence of CAA demands continuous assessment of coronary arteries anatomy and myocardial perfusion evaluation to assess the need of potential intervention.

Regarding brain MRI, it has an important value in the evaluation of neurologic deficits after MIS-C and can guide further treatment.

**Conclusion**

Although rare, MIS-C involves many vital organs including heart and brain. Patients with MIS-C should be treated in hospital and may need intensive care unit. Imaging modalities including echocardiography and CMR may guide successfully the effect on cardiovascular disease of both supportive and anti-inflammatory medication. Furthermore, brain MRI can reveal brain involvement, which may have significant clinical implications both in acute and follow-up periods and should be treated adequately.

**Funding** Not applicable.

**Declarations**

**Conflict of interest** Authors declare no relevant conflict of interest.

**Disclaimer** No parts of the final version of the manuscript contain copied parts and all co-authors take full responsibility for the integrity of the published article.

**Availability of data and material** Not applicable.

**References**

1. Abrams JY, Godfred-Cato SE, Oster ME et al (2020) Multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2: a systematic review. J Pediatr 226:45-54.e1. https://doi.org/10.1016/j.jpeds.2020.08.003
2. Akca UK, Kesici S, Ozsurekci Y et al (2020) Kawasaki-like disease in children with COVID-19. Rheumatol Int 40:2105–2115. https://doi.org/10.1007/s00296-020-04701-6
3. Licciardi F, Pruccoli G, Denina M et al (2020) SARS-CoV-2-Induced Kawasaki-like hyperinflammatory syndrome: a novel COVID phenotype in children. Pediatrics. https://doi.org/10.1542/peds.2020-1711
4. Singh S, Jindal AK, Pilania RK (2018) Diagnosis of Kawasaki disease. Int J Rheum Dis 21:36–44. https://doi.org/10.1111/1756-185X.13224
5. Singh S, Vignesh P, Burgnner D (2015) The epidemiology of Kawasaki disease: a global update. Arch Dis Child 100:1084–1088. https://doi.org/10.1136/archdischild-2014-307536
6. Whitaker E, Bamford A, Kenny J et al (2020) Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA - J Am Med Assoc 324:259–269. https://doi.org/10.1001/jama.2020.10369
7. Parri N, Lengé M, Buonsenso D (2020) Children with Covid-19 in pediatric emergency departments in Italy. N Engl J Med 383:187–190. https://doi.org/10.1056/nejmep2007617
8. Radia T, Williams N, Agrawal P et al (2020) Multi-system inflammatory syndrome in children & adolescents (MIS-C): a systematic review of clinical features and presentation. Paediatr Respir Rev. https://doi.org/10.1016/j.prrv.2020.08.001
9. Information for Healthcare Providers about Multisystem Inflammatory Syndrome in Children (MIS-C) | CDC. https://www.cdc.gov/mis-c/hcp/. Accessed 6 Feb 2021
10. Han SB, Lee SY (2020) Macrophage activation syndrome in children with Kawasaki disease: diagnostic and therapeutic approaches. World J Pediatr 16:556–574. https://doi.org/10.1007/s12519-020-00360-6
11. Kabeerdoss J, Pilania RK, Karkhele R et al (2021) Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: immunological mechanisms, clinical manifestations and management. Rheumatol Int 41:19–32. https://doi.org/10.1007/s00296-020-04749-4
12. Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409–1417. https://doi.org/10.1007/s00296-011-1999-3
13. Pouletty M, Borocco C, Ouldali N et al (2020) Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. Ann Rheum Dis 79:999–1006. https://doi.org/10.1136/annrheumdis-2020-217960
14. Belhadjer Z, Mété M, Bajolle F et al (2020) Acute heart failure in multisystem inflammatory syndrome in children in the context of global SARS-CoV-2 pandemic. Circulation 142:429–436. https://doi.org/10.1161/CIRCULATIONAHA.120.048360
15. Pilania RK, Bhattarai D, Singh S (2018) Controversies in diagnosis and management of Kawasaki disease. World J Clin Pediatr 7:27–35. https://doi.org/10.5409/wjcp.v7.i1.27
16. Dionne A, Mah DY, Son MBF (2020) Atrioventricular block in children with multisystem inflammatory syndrome. Pediatrics. https://doi.org/10.1542/peds.2020-09704
17. Pilania RK, Jindal AK, Bhattarai D et al (2020) Cardiovascular involvement in kawasaki disease is much more than mere coronary arteritis. Front Pediatr. https://doi.org/10.3389/fped.2020.520699
18. Toubiana J, Poirault C, Corsia A et al (2020) Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ 369:m2094. https://doi.org/10.1136/bmj.m2094
19. Lee PY, Day-Lewis M, Henderson LA et al (2020) Distinct clinical and immunological features of SARS–CoV-2–induced multisystem inflammatory syndrome in children. J Clin Invest 130:5942–5950. https://doi.org/10.1172/JCI11113
20. Cheung EW, Zachariah P, Gorelik M et al (2020) Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City. JAMA J Am Med Assoc 324:294–296. https://doi.org/10.1001/jama.2020.10374
21. Ramcharan T, Nolan O, Lai CY et al (2020) Paediatric inflammatory multisystem syndrome: temporarily associated with SARS-CoV-2 (PIMS-TS): cardiac features, management and short-term outcomes at a UK Tertiary Paediatric Hospital. Pediatr Cardiol 41:1391–1401. https://doi.org/10.1007/s00246-020-02391-2
22. Reddy M, Singh S, Rawat A et al (2016) Pro-brain natriuretic peptide (ProBNP) levels in North Indian children with Kawasaki disease. Rheumatol Int 36:551–559. https://doi.org/10.1007/s00296-016-3430-6
23. Feldstein LR, Rose EB, Horwitz SM et al (2020) Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med 383:334–346. https://doi.org/10.1056/nejmoa201680
24. Valverde I, Singh Y, Sanchez-de-Toledo J et al (2021) Acute Cardiovascular Manifestations in 286 Children With Multisystem Inflammatory Syndrome Associated With COVID-19 Infection in Europe. Circulation 143:21–32. https://doi.org/10.1161/CIRCULATIONAHA.120.05065
25. Regan W, O’Byrne L, Stewart K et al (2021) Electrocardiographic changes in children with multisystem inflammation associated with COVID-19. J Pediatr. https://doi.org/10.1016/j.jpeds.2020.12.033
26. Matsubara D, Kauffman HL, Wang Y et al (2020) Echocardiographic findings in pediatric multisystem inflammatory syndrome associated with COVID-19 in the United States. J Am Coll Cardiol 76:1947–1961. https://doi.org/10.1016/j.jacc.2020.08.056
27. Son MBF, Newburger JW (2018) Kawasaki disease. Pediatr Rev 39:78–90. https://doi.org/10.1542/pir.2016-0182
28. Mavrogeni S, Papadopoulos G, Hussain T et al (2013) The emerging role of cardiovascular magnetic resonance in the evaluation of Kawasaki disease. Int J Cardiovasc Imaging 29:1787–1798. https://doi.org/10.1007/s10554-013-0276-9
29. Friedman KG, Harrild DM, Newburger JW (2020) Cardiac dysfunction in multisystem inflammatory syndrome in children: a call to action. J Am Coll Cardiol 76:1962–1964. https://doi.org/10.1016/j.jacc.2020.09.002
30. Kelly MS, Valle CW, Fernandes ND et al (2020) Multisystem inflammatory syndrome in Children: cardiac biomarker profiles and echocardiographic findings in the acute and recovery phases. J Am Soc Echocardiogr 33:1288–1290. https://doi.org/10.1016/j.echo.2020.08.008
31. Friedrich MG, Sechtem U, Schulz-Menger J et al (2009) Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol 53:1475–1487. https://doi.org/10.1016/j.jacc.2009.02.007
32. Cau R, Bassareo PP, Mannelli L et al (2020) Imaging in COVID-19-related myocardial injury. Int J Cardiovasc Imaging. https://doi.org/10.1007/s10554-020-02089-9
33. Ferreira VM, Schulz-Menger J, Holmvang G et al (2018) Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol 72:3158–3176. https://doi.org/10.1016/j.jacc.2018.09.072
34. Punemann VO, Carerj ML, Wieters I et al (2020) Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 5:1265–1273. https://doi.org/10.1001/jamacardio.2020.3557
35. Blondiaux E, Pariset P, Redheuil A et al (2020) Cardiac MRI in children with multisystem inflammatory syndrome associated with COVID-19. Radiology 297:E283–E288. https://doi.org/10.1148/radiol.2020202288
36. Mavrogeni S, Papadopoulos G, Douskou M et al (2004) Magnetic resonance angiography is equivalent to X-Ray coronary angiography for the evaluation of coronary arteries in kawasaki disease. J Am Coll Cardiol 43:649–652. https://doi.org/10.1016/j.jacc.2003.08.052
37. Mavrogeni S, Papadopoulos G, Douskou M et al (2006) Magnetic resonance angiography, function and viability evaluation in patients with Kawasaki disease. J Cardiovasc Magn Reson 8:493–498. https://doi.org/10.1080/10976640600604773
38. Henderson LA, Canna SW, Friedman KG et al. (2020) American College of Rheumatology Clinical Guidance for Pediatric Patients with Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 and Hyperinflammation

© Springer
39. Mahammedi A, Saba L, Vagal A et al (2020) Imaging of neurologic disease in hospitalized patients with COVID-19: An italian multicenter retrospective observational study. Radiology 297:E270–E273. https://doi.org/10.1148/RADIOL.2020201933

40. Chiotos K, Bassiri H, Behrens EM et al (2020) Multisystem inflammatory syndrome in children during the Coronavirus 2019 pandemic: a case series. J Pediatr Infect Dis Soc 9:393–398. https://doi.org/10.1093/jpids/piaa069

41. Verdoni L, Mazza A, Gervasoni A et al (2020) An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet 395:1771–1778. https://doi.org/10.1016/S0140-6736(20)31103-X

42. Dufort EM, Koumans EH, Chow EJ et al (2020) Multisystem inflammatory syndrome in children in New York State. N Engl J Med 383:347–358. https://doi.org/10.1056/nejmoa2021756

43. Chen TH (2020) Neurological involvement associated with COVID-19 infection in children. J Neurol Sci. https://doi.org/10.1016/j.jns.2020.117096

44. Román GC, Spencer PS, Reis J et al (2020) The neurology of COVID-19 revisited: a proposal from the Environmental Neurology Specialty Group of the World Federation of Neurology to implement international neurological registries. J Neurol Sci. https://doi.org/10.1016/j.jns.2020.116884

45. Bektaş G, Akçay N, Boydağ K, Şevketoğlu E (2021) Reversible splenial lesion syndrome associated with SARS-CoV-2 infection in two children. Brain Dev 43:230–233. https://doi.org/10.1016/j.braindev.2020.10.002

46. Hacohen Y, Abdel-Mannan O, Eyre M et al (2020) Neurologic and radiographic findings associated with COVID-19 infection in children. JAMA Neurol 77:1440–1445. https://doi.org/10.1001/jamaneurol.2020.2687

47. Abel D, Shen MY, Abid Z et al (2020) Encephalopathy and bilateral thalamic lesions in a child with MIS-C associated with COVID-19. Neurology 95:745–748. https://doi.org/10.1212/WNIL.0000000000010652

48. Fenlon EP III, Chen S, Ruzal-Shapiro CB et al (2021) Extra-cardiac imaging findings in COVID-19-associated multisystem inflammatory syndrome in children. Pediatr Radiol. https://doi.org/10.1007/s00247-020-04929-1